1文献来源Liu SY,Dong S,Yang XN,et al.Neoadjuvant nivolumab with or without platinum⁃doublet chemotherapy based on PD⁃L1 expression in resectable NSCLC(CTONG1804):a multicenter open⁃label phaseⅡstudy[J].Signal Transdu...1文献来源Liu SY,Dong S,Yang XN,et al.Neoadjuvant nivolumab with or without platinum⁃doublet chemotherapy based on PD⁃L1 expression in resectable NSCLC(CTONG1804):a multicenter open⁃label phaseⅡstudy[J].Signal Transduct Target Ther,2023,8(1):442.2证据水平2a。展开更多
1文献来源研究一:Saalfeld FC,Wenzel C,Christopoulos P,et al.Efficacy of immune checkpoint inhibitors alone or in combination with chemotherapy in NSCLC harboring ERBB2 mutations[J].J Thorac Oncol,2021,16(11):1952-1958...1文献来源研究一:Saalfeld FC,Wenzel C,Christopoulos P,et al.Efficacy of immune checkpoint inhibitors alone or in combination with chemotherapy in NSCLC harboring ERBB2 mutations[J].J Thorac Oncol,2021,16(11):1952-1958.研究二:Yang G,Yang Y,Liu R,et al.First⁃line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2⁃altered NSCLC:a retrospective real⁃world POLISH study[J].Ther Adv Med Oncol,2022,14:17588359221082339.展开更多
Background Serum expression of cytokines may provide information about the clinical outcome of advanced non-small cell lung cancer （NSCLC） patients. This study aimed to investigate the relationship between serum cyt...Background Serum expression of cytokines may provide information about the clinical outcome of advanced non-small cell lung cancer （NSCLC） patients. This study aimed to investigate the relationship between serum cytokine levels and the clinical outcome of erlotinib treatment in a second or third line setting in patients with advanced NSCLC.展开更多
文摘1文献来源Liu SY,Dong S,Yang XN,et al.Neoadjuvant nivolumab with or without platinum⁃doublet chemotherapy based on PD⁃L1 expression in resectable NSCLC(CTONG1804):a multicenter open⁃label phaseⅡstudy[J].Signal Transduct Target Ther,2023,8(1):442.2证据水平2a。
文摘1文献来源研究一:Saalfeld FC,Wenzel C,Christopoulos P,et al.Efficacy of immune checkpoint inhibitors alone or in combination with chemotherapy in NSCLC harboring ERBB2 mutations[J].J Thorac Oncol,2021,16(11):1952-1958.研究二:Yang G,Yang Y,Liu R,et al.First⁃line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2⁃altered NSCLC:a retrospective real⁃world POLISH study[J].Ther Adv Med Oncol,2022,14:17588359221082339.
文摘Background Serum expression of cytokines may provide information about the clinical outcome of advanced non-small cell lung cancer （NSCLC） patients. This study aimed to investigate the relationship between serum cytokine levels and the clinical outcome of erlotinib treatment in a second or third line setting in patients with advanced NSCLC.
